STROMUSC Cialis(Tadalafil)20mg Treatment For ED CAS:171596-29-5

    Core Identity & Mechanism: Beyond Simple PDE5 Inhibition

     ●What it Is: Tadalafil is a selective, reversible inhibitor of phosphodiesterase type 5 (PDE5), the enzyme predominant in the corpus cavernosum of the penis. Its inhibition is the cornerstone of its ED action.

    ●The Nitric Oxide (NO)-cGMP Pathway Revisited: Sexual stimulation triggers NO release in penile tissue. NO activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) levels. cGMP relaxes smooth muscle in the penile arteries and corpus cavernosum, enabling blood inflow and erection. PDE5 normally degrades cGMP, terminating the signal. Tadalafil's critical action is prolonging the lifespan and amplifying the effect of naturally released cGMP by inhibiting PDE5. It does not directly cause erection but requires sexual stimulation to potentiate the natural physiological response.

    ●Selectivity Nuance: While highly selective for PDE5, tadalafil exhibits mild affinity for PDE11 (found in skeletal muscle, testes, pituitary, heart, liver). The clinical significance of PDE11 inhibition remains debated but is considered minimal at therapeutic doses, contributing primarily to muscle ache side effects in some individuals.

    1.Extended Plasma Half-Life: ~17.5 hours. This is tadalafil's most defining characteristic. Unlike sildenafil (~3-5 hours) or vardenafil (~4-5 hours), tadalafil's prolonged presence allows for unique dosing flexibility. This isn't merely "longer"; it fundamentally shifts the treatment paradigm from an "on-demand" focus to include "preemptive readiness."

    2.Steady-State Kinetics: Due to its half-life, steady-state plasma concentrations are achieved after approximately 5 days of once-daily dosing. This underpins the chronic dosing strategy.

    3.Rapid Absorption & Food Independence: Tadalafil is absorbed relatively quickly (median Tmax ~2 hours), and crucially, absorption is not significantly impaired by food intake (including high-fat meals). This contrasts sharply with sildenafil, offering greater convenience and reliability regardless of meal timing.

    4.Linear Pharmacokinetics: Dose increases generally lead to proportional increases in plasma concentration (AUC and Cmax), simplifying dose adjustment.

    5.Tissue Penetration & Duration of Effect: While plasma levels decline with the half-life, the functional window for response is notably long – up to 36 hours post-dose for the as-needed regimen. This extended therapeutic window is attributed to effective tissue penetration and sustained PDE5 inhibition at the target site beyond what plasma levels alone might suggest. This facilitates spontaneous sexual activity without precise scheduling.

    6.Dual Indication: Tadalafil is uniquely approved for both ED and the signs and symptoms of Benign Prostatic Hyperplasia (BPH). The mechanism for BPH involves smooth muscle relaxation in the prostate and bladder neck, also mediated via the NO-cGMP pathway and PDE5 inhibition, reducing urinary obstruction and irritation. Lower daily doses (2.5mg or 5mg) are typically used for BPH or ED/BPH combination therapy.

    ●Primary Application: Treatment of Erectile Dysfunction of various etiologies (vascular, diabetic, post-prostatectomy, psychogenic).

    ●Key Benefits & Clinical Advantages:

    ○The "36-Hour Window": This is not marketing hyperbole but a clinically observed functional period. It reduces the performance anxiety associated with strictly timed medication intake (e.g., 1 hour before), fostering a more natural and spontaneous sexual experience. Couples report significantly improved sexual satisfaction related to reduced planning pressure.

    ○Dosing Flexibility: Offers two distinct, evidence-based strategies:

    ◇On-Demand (As-Needed): 10mg or 20mg taken at least 30 minutes before anticipated sexual activity. The 36-hour window provides ample flexibility.

    ◇Once-Daily (Chronic Low-Dose): 2.5mg or 5mg taken consistently at approximately the same time each day. This maintains therapeutic plasma levels, enabling spontaneity without any dosing decision related to sexual activity. Ideal for men anticipating frequent sexual activity (e.g., ≥ twice weekly) or those preferring a "set it and forget it" approach. Particularly beneficial for men with partners experiencing menopause-related dyspareunia requiring more time/lubrication, as it removes the male partner's timing pressure.

    ○Food Compatibility: Eliminates dietary restrictions, enhancing user-friendliness and adherence compared to older PDE5 inhibitors.

    ○Consistent Efficacy: The chronic dosing regimen provides constant coverage, potentially leading to more reliable responses over time and improved endothelial function with prolonged use (an area of ongoing research).

    ○Dual Benefit for ED/BPH: A single medication addressing two common, bothersome conditions in aging men simplifies treatment regimens and improves quality of life metrics related to both sexual function and urination.

    ●Standard Dosing Options:

    ○On-Demand: Initiated at 10mg before sexual activity. Based on efficacy and tolerability, can be increased to 20mg or decreased to 5mg. Minimum dosing interval: 24-48 hours (driven by half-life and avoiding accumulation/side effects).

    ○Once-Daily: Initiated at 2.5mg or 5mg. The 5mg dose is most common for ED monotherapy. The 2.5mg dose may be used if 5mg is not tolerated or for BPH/combination therapy. Taken daily without regard to timing of sexual activity.

    ●"Cycle" Concept: Unlike anabolic steroids, PDE5 inhibitors don't operate in traditional "cycles." However, the dosing strategies represent distinct regimens:

    ○The As-Needed Cycle: Characterized by intermittent dosing aligned with anticipated sexual activity, leveraging the long functional window. Dosing frequency varies per individual's sexual pattern.

    ○The Chronic Cycle: Characterized by continuous daily dosing, maintaining steady-state inhibition. Requires consistent intake. There's no defined "on/off" period; discontinuation leads to a gradual decline in plasma levels over ~5 half-lives (~3.5 days).

    ●Half-Life Dynamics & Practical Implications: The ~17.5-hour half-life means:

    ○It takes about 5 days (5 x half-life) to reach steady-state on daily dosing.

    ○After stopping daily dosing, it takes about 3.5 days for the drug to be mostly eliminated (97%).

    ○For on-demand dosing, accumulation is minimal if taken no more than once every 24-48 hours.

    ○This long half-life necessitates caution with interacting drugs (see below) and in populations with altered metabolism.

    ●Dose Adjustment Imperatives:

    ○Renal Impairment: Moderate (CrCl 30-50 mL/min): Max on-demand dose 10mg; Daily dose max 5mg. Severe (CrCl <30 mL/min) or Dialysis: On-demand use not recommended; Max daily dose 5mg (use not recommended in ESRD by some guidelines).

    ○Hepatic Impairment: Mild or Moderate (Child-Pugh A or B): Max recommended dose 10mg on-demand or 5mg daily. Severe (Child-Pugh C): Not studied, use not recommended.

    ○Drug Interactions: Crucially Important: Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice) significantly increase tadalafil exposure.

    ◇With potent CYP3A4 inhibitors: Max recommended on-demand dose is 10mg no more than once every 72 hours; Max daily dose is 2.5mg.

    ○Alpha-Blockers: Use with caution due to potential additive blood pressure lowering. Initiate tadalafil only if patient is stable on alpha-blocker therapy. Start with the lowest tadalafil dose (5mg on-demand or 2.5mg daily). Avoid concurrent use with multiple antihypertensives or significant cardiovascular instability.

    ○Nitrates: ABSOLUTE CONTRAINDICATION. Concomitant use can cause severe, life-threatening hypotension.

    Cialis carved its niche not just by being "another PDE5i" but by introducing temporal flexibility into ED treatment. The long half-life and resulting 36-hour functional window for on-demand use, coupled with the validated once-daily dosing option, addressed core psychological and practical barriers to ED treatment – performance anxiety and the need for rigid scheduling. The food independence further enhanced its real-world usability. Its dual indication for BPH offers a unique advantage for a significant patient subset. While efficacy rates across PDE5 inhibitors are broadly similar in clinical trials, tadalafil's pharmacokinetic profile provides distinct quality-of-life benefits related to spontaneity and convenience, factors highly valued in real-world adherence and satisfaction.

    ●Not an Aphrodisiac: Requires sexual stimulation.

    ●Cardiovascular Assessment: ED can be an early marker of cardiovascular disease. A cardiovascular evaluation is often appropriate before initiating treatment, especially in men with risk factors. Tadalafil is generally safe in stable cardiovascular disease but contraindicated in unstable angina, recent MI, severe heart failure, uncontrolled arrhythmias, or hypotension.

    ●Priapism: Prolonged (>4 hours), painful erection is rare but requires emergency treatment to prevent tissue damage. More common in men with sickle cell anemia, leukemia, or penile deformities.

    ●NAION: Non-arteritic anterior ischemic optic neuropathy (sudden vision loss) has been reported rarely. Risk may be increased in those with underlying anatomic or vascular risk factors.

    ●Hearing Loss: Sudden decrease or loss has been reported rarely.

    ●Common Side Effects: Headache, dyspepsia, back pain, myalgia, nasal congestion, flushing, dizziness. Back pain/myalgia are more commonly reported with tadalafil than other PDE5i, likely related to PDE11 inhibition.

    ●Absolute Contraindications: Nitrate therapy (any form), hypersensitivity to tadalafil.

    ●Medical Supervision Mandatory: Tadalafil is a prescription medication. Initiation and dose adjustment must be under the guidance of a qualified healthcare provider who understands the patient's full medical history, current medications, and contraindications.

Brand	STROMUSC
Trade names	Cialis, Cidala, Adcirca,Tadalafil
CAS	171596-29-5
Molar mass	389.41
Formula	C22H19N3O4
Purity	Above 98%
Apprarance	20mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    Cialis (tadalafil) revolutionized ED management through its extended pharmacokinetic profile, enabling both effective on-demand use with a generous 36-hour window and convenient once-daily chronic therapy. This unique temporal flexibility directly addresses key psychological barriers to ED treatment. Its food compatibility and dual indication for BPH further enhance its clinical utility and patient-centric design. Understanding its prolonged half-life (~17.5 hours) is crucial for safe prescribing, particularly regarding dose adjustments in special populations and avoidance of dangerous drug interactions (especially nitrates and potent CYP3A4 inhibitors). While not a cure, tadalafil offers a highly effective, versatile, and well-tolerated option for restoring erectile function, significantly improving sexual quality of life for millions of men when used appropriately under medical supervision. Its distinct characteristics ensure it remains a cornerstone therapy in the urologist's and primary care provider's armamentarium.

Hot Tags: stromusc cialis(tadalafil)20mg treatment for ed cas:171596-29-5, China stromusc cialis(tadalafil)20mg treatment for ed cas:171596-29-5 manufacturers, suppliers, factory